Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9139167 | 0.86 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9139155 | 0.86 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL4788784 | 0.77 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9139881 | 0.77 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL4788789 | 0.77 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9846838 | 0.75 | ALDH1A1 (0.39) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9846852 | 0.75 | ALDH1A1 (0.39) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9846845 | 0.75 | ALDH1A1 (0.39) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9250982 | 0.72 | MGAM (0.36) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL14529652 | 0.64 | OPRM1 (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0642353-A1 | TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS | ONCOLOGIX, INC. (US) | 1995-03-15 | — | — | EP | claimed |
| WO-1993023075-A1 | TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS | ONCOLOGIX, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| US-5866570-A | Treatment of vascular leakage and related syndrome such as septic shock by administration of metalloproteinase inhibitors | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0642353-A1 | TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS | ONCOLOGIX, INC. (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993023075-A1 | TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS | ONCOLOGIX, INC. (US) | 1993-11-25 | — | — | WO | disclosed |